Previously, patients with lung non-adenocarcinoma, such as large cell lung carcinomas (LCLCs), harboring EGFR mutations and treated with EGFR-TKIs, also had a reduced mPFS (4.4 months) (20). The gene discussed is EGFR; the disease is lung large cell carcinoma.